The Iron Chelator Deferiprone Improves the Phenotype in a Mouse Model of Tauopathy
Shalini S Rao, Stuart D Portbury, Larissa Lago, Ashley Bush, Paul A Adlard
JOURNAL OF ALZHEIMERS DISEASE | IOS PRESS | Published : 2020
BACKGROUND: Abnormally hyperphosphorylated tau is a defining pathological feature of tauopathies, such as Alzheimer's disease (AD), and accumulating evidence suggests a role for iron in mediating tau pathology that may lead to cognitive decline in these conditions. The metal chelator deferiprone (DFP), which has a high affinity for iron, is currently in clinical trials for AD and Parkinson's disease. However, the effect of DFP on tau pathology remains underexplored. OBJECTIVE: We aimed to investigate the impact of chronic DFP treatment on tau pathology using a well-characterized mouse model of tauopathy (rTg(tauP301L)4510). METHODS: Animals were treated daily with DFP (100 mg/kg) via oral ga..View full abstract
The Florey Institute of Neuroscience and Mental Health acknowledge the strong support from the Victorian Government and in particular the funding from the Operational Infrastructure Support Grant. The authors would like to thank A/Prof Blaine Roberts and the Neuroproteomics Facility (Florey) for the use of the SEC-ICPMS equipment and Irene Volitakis for generating the preliminary ICP-MS data. SSR would also like to thank the Core Animal Services staff and other members of the Florey and The Melbourne Dementia Research Centre for their assistance throughout the project and was supported by a Parkinson's Victoria-Argyrou Family PhD Partner Scholarship.